World Health Organization. Obesity: Preventing And Managing The Global Epidemic. 1997, Geneva.
Blagojevic M, Jinks C, Jeffery A, Jordan Kp. Risk Factors For Onset Of Osteoarthritis Of The Knee In Older Adults: A Systematic Review And Meta-Analysis. Osteoarthritis Cartilage, 2010 Jan, 18(1): 24-33. doi: 10.1016/J.Joca.2009.08.010..
DOI: 10.1016/J.Joca.2009.08.010
Fu Y, Griffin TM. Obesity, Osteoarthritis And Aging: The Biomechanical Links. Mechanobiology Of Obesity And Related Diseases. Springer International Publishing, 2015: 181-201.
Кашеварова Н.Г., Алексеева Л.И., Таскина Е.А., Смирнов А.В. Ведущие факторы прогрессирования остеоартрита коленных суставов. Влияние симптоматических препаратов замедленного действия на течение заболевания (5-летнее проспективное исследование). Фарматека, 2017, 7(340): 40-45.
Wang H et al. Metabolic Syndrome Increases The Risk For Knee Osteoarthritis: A Meta-Analysis. Evid Based Complement Alternat Med, 2016, 2016: 7242478.
Morley Je, Sinclair A. The Metabolic Syndrome In Older Persons: A Loosely Defined Constellation Of Symptoms Or A Distinct Entity? Age Ageing, 2009, 38(5): 494-7. doi: 10.1093/Ageing/Afp105. Epub 2009 Jul 2..
DOI: 10.1093/Ageing/Afp105. Epub 2009 Jul 2
Тареев Е.М. Гипертоническая болезнь. М.: Медгиз, 1948. 156 с.
Hanefeld M, Schaper F, Ceriello A. Geschichte Und Definition (En) Des Metabolischen Syndroms. Internist, 2007, 48: 117-25.
Диагностика и лечение метаболического синдрома. Сборник национальных клинических рекомендаций. М.: Силицея – Полиграф, 2009: 106-143.
Стребкова Е.А., Алексеева Л.И. Остеоартроз и ожирение. Научно-практическая ревматология, 2015, 53(5): 542-552.
Singh G, Miller JD, Lee FH, Pettitt D, and Russell MW. Prevalence Of Cardiovascular Disease Risk Factors Among Us Adults With Self-Reported Osteoarthritis: Data From The Third National Healt Hand Nutrition Examination Survey. American Journal Of Managed Care, 2002, 8(15): 383–391.
Shin D. Association Between Metabolic Syndrome, Radiographic Knee Osteoarthritis, And Intensity Of Knee Pain: Results Of A National Survey. J. Clin. Endocrinol. & Metab., 2014, 99(9): 3177–3183.
Velasquez MT, Katz JD. Osteoarthritis: Another Component Of Metabolic Syndrome? Metab. Syndr. Relat. Disord., 2010, 8(4): 295–305.
Yoshimura N, Muraki S, Oka H, Tanaka S, Kawaguchi H, Nakamura K, Akune T. Accumulation Of Metabolic Risk Factors Such As Overweight, Hypertension, Dyslipidaemia, And Impaired Glucose Tolerance Raises The Risk Of Occurrence And Progression Of Knee Osteoarthritis: A 3-Year Follow-Up Of The Road Study. Osteoarthritis Cartilage, 2012 Nov, 20(11): 1217-26. doi: 10.1016/j. joca.2012.06.006..
DOI: 10.1016/j. joca.2012.06.006
Yoshimura N, Muraki S, Oka H, Kawaguchi H, Nakamura K, Akune T. A ssociation Of Knee Osteoarthritis With The Accumulation Of Metabolic Risk Factors Such As Overweight, Hypertension, Dyslipidemia,And Impaired Glucose Tolerance In Japanese Men And Women: The Road Study. J Rheumatol., 2011, 38(5): 921-30. doi: 10.3899/Jrheum.100569..
DOI: 10.3899/Jrheum.100569
Abourazzak F, Talbi S, Lazrak F, Azzouzi H, Aradoini N, Keita S, Errasfa M, Harzy T. Does Metabolic Syndrome Or Its Individual Components Affect Pain And Function In Knee Osteoarthritis Women? Curr Rheumatol Rev, 2015 May 21.
Chadha R. Revealed aspect of metabolic osteoarthritis. J Orthop, 2016 Jul 9, 13(4): 347-51. doi: 10.1016/j.jor.2016.06.029. eCollection 2016 Dec..
DOI: 10.1016/j.jor.2016.06.029. eCollection 2016 Dec
Farnaghi S, Crawford R, Xiao Y, Prasadam I. Cholesterol metabolism in pathogenesis of osteoarthritis disease. Int J Rheum Dis, 2017 Feb, 20(2): 131-140. doi: 10.1111/1756-185X.13061. Epub 2017 Apr 5..
DOI: 10.1111/1756-185X.13061. Epub 2017 Apr 5
Dellisola A, Allan R, Smith S, Marreiros Ss, Steultjens M. Identification Of Clinical Phenotypes In Knee Osteoarthritis: A Systematic Review Of The Literature. BMC mus-culoskelet disord, 2016 Oct 12, 17(1): 425. doi: 10.1186/s12891-016-1286-2..
DOI: 10.1186/s12891-016-1286-2
Martel-Pelletier J, Pelletier JP. Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis, 2010 Apr, 2(2): 95-104. doi: 10.1177/1759720X09359104..
DOI: 10.1177/1759720X09359104
Steinecker-Frohnwieser B, Kaltenegger H, Weigl L, Mann A, Kullich W, Leithner A, Lohberger B. Pharmacological treatment with diacerein combined with mechanical stimulation affects the expression of growth factors in human chondrocytes. Biochem Biophys Rep, 2017 Jul 1, 11: 154-160. doi: 10.1016/j. bbrep.2017.06.006..
DOI: 10.1016/j. bbrep.2017.06.006
Sun H, Luo G, Chen D, Xiang Z. A Comprehensive and System Review for the Pharmacological Mechanism of Action of Rhein, an Active Anthraquinone Ingredient. Front Pharmacol, 2016 Aug 17, 7: 247. doi: 10.3389/fphar.2016.00247. eCollection 2016..
DOI: 10.3389/fphar.2016.00247. eCollection 2016
Алексеева Л.И., Кашеварова Н.Г., Таскина Е.А., Шарапова Е.П., Аникин С.Г., Короткова Т.А., Стребкова Е.А. Эффективность и безопасность диацереина у пациентов с остеоартритом коленных суставов. Современная ревматология, 2017, 11(3): 50–57.
Шарапова Е.П., Кашеварова Н.Г., Зайцева Е.М., Аникин С.Г., Короткова Т.А., Алексеева Л.И. Оценка эффективности и безопасности диацереина у пациентов с остеоартрозом тазобедренных суставов. Медицинский совет, 2017, 1s: 84-89.
Каратеев А.Е., Алексеева Л.И., Цурган А.В., Гонтаренко Н.В. Оценка эффективности и безопасности комплексной терапии скелетно-мышечной боли с использованием Диацереина (по данным исследования РОКАДА – ретроспективная оценка клинических аспектов применения диафлекса при остеоартрозе). Неврология и ревматология. Приложение к журналу Consilium Medicum, 2016, 2: 26-32.
Pavelka K, Bruyere O, Cooper C et al. Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs Aging, 2016, 33(2): 75–85. doi: 10.1007/s40266-016-0347-4..
DOI: 10.1007/s40266-016-0347-4
Assessment report for diacerein containing medicinal products. 28 August 2014 EMA/527347/2014. http: //www.ema.europa. eu/.
Joo NS, Kim SM, Kim KM, Kim CW, Kim BT, Lee DJ. Changes of body weight and inflammatory markers after 12-week intervention trial: results of a double-blind, placebo-control pilot study. Yonsei Med J, 2011 Mar, 52(2): 242-8. doi: 10.3349/ymj.2011.52.2.242..
DOI: 10.3349/ymj.2011.52.2.242
Наумов А.В., Ховасова Н.О. Рекомендованная терапия остеоартрита: новые решения старых задач. РМЖ, 2016, 24(3): 197-202.
Ramos-Zavala MG, Gonzalez-Ortiz M, Martinez-Abundis E, Robles-Cervantes JA, Gonzalez-Lopez R, Santiago-Hernandez NJ. Effect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized clinical trial. Diabetes Care, 2011 Jul, 34(7): 1591-4. doi: 10.2337/dc11-0357..
DOI: 10.2337/dc11-0357
Villar MM, Martinez-Abundis E, Preciado-Mаrquez RO, Gonzalez-Ortiz M.Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. Arch Endocrinol Metab, 2017 Mar-Apr, 61(2): 188-192. doi: 10.1590/2359-3997000000242..
DOI: 10.1590/2359-3997000000242
Cardoso CRL, Leite NC, Carlos FO, Loureiro AA, Viegas BB, Salles GF. Efficacy and Safety of Diacerein in Patients With Inadequately Controlled Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care, 2017 Aug 17. pii: dc170374. doi: 10.2337/dc17-0374..
DOI: 10.2337/dc17-0374
Tobar N, Oliveira AG, Guadagnini D, et al. Diacerhein improves glucose tolerance and insulin sensitivity in mice on a high-fat diet. Endocrinology, 2011, 152: 4080–4093.
Hotamisligil GS. Inflammation and metabolic disorders. Nature, 2006, 444: 860-7.
Du H, Shao J, Gu P, Lu B, Ye X, Liu Z. Improvement of glucose tolerance by rhein with restored early-phase insulin secretion in db/db mice. J Endocrinol Invest, 2012, 35: 607– 612.
Liu J, Chen Z, Zhang Y, et al. Rhein protects pancreatic b-cells from dynamin-related protein- 1-mediated mitochondrial fission and cell apoptosis under hyperglycemia. Diabetes, 2013, 62: 3927–393.
Malaguti C, Vilella CA, Vieira KP, Souza GH, Hyslop S, Zollner RdeL. Diacerhein downregu-late proinflammatory cytokines expression and decrease the autoimmune d iabetes frequency in nonobese diabetic (NOD) mice. Int Immunopharmacol, 2008, 8: 782–791.
Li H, George DM, Jaarsma RL, Mao X. Metabolic syndrome and components exacerbate osteoarthritis symptoms of pain, depression and reduced knee function. Ann Transl Med, 2016 Apr, 4(7): 133. doi: 10.21037/atm.2016.03.48..
DOI: 10.21037/atm.2016.03.48
Tootsi K, Mаrtson A, Kals J, Paapstel K, Zilmer M. Metabolic factors and oxidative stress in osteoarthritis: a case-control study. Scand J Clin Lab Invest, 2017 Jul, 24: 1-7. doi: 10.1080/00365513.2017.1354255..
DOI: 10.1080/00365513.2017.1354255
Yasuda E, Nakamura R, Matsugi R, Goto S, Ikenaga Y, Kuroda K, Nakamura S, Katsuki Y, Katsuki T. Association between the severity of symptomatic knee osteoarthritis and cumulative metabolic factors. Aging Clin Exp Res, 2017 Jul 31. doi: 10.1007/s40520-017-0808-6..
DOI: 10.1007/s40520-017-0808-6
Jatwa R, Kar А. Anti-inflammatory and anti-per-oxidative roles of diacerein are possibly mediated through an alteration in thyroid functions in animal model of inflammation. Fundamental & Clinical Pharmacology, 2009 Jun, 23(4): 465–471.
Sheng X, Wang M, Lu M, Xi B, Sheng H, Zang YQ. Rhein ameliorates fatty liver disease through negative energy balance, hepatic lipogenic regulation, and immunomodulation in diet-induced obese mice. Am J Physiol Endocrinol Metab, 2011, 300: 886–893.
Lin YJ, Hu G, Li KJ, Zhao YF, Wei J, Zhen YZ. The protection of rhein lysinate to liver in diabetic mice induced by high-fat diet and streptozotocin. Arch Pharm Res, 2015, 38: 885–892.
Guo MZ, Li XS, Xu HR, Mei ZC, Shen W, and Ye XF. Rhein inhibits liver fibrosis induced by carbon tetrac hloride in rats. Acta Pharmacologica Sinica, 2002, 23(8): 739–744.